As MHT acts by binding to oestrogen receptors (ER<i>α</i> and ER<i>β</i>), we used drug-target Mendelian randomisation (MR) to test whether perturbing these targets alters the risk of Alzheimer's disease (AD), brain structure, depression, or anxiety. Here, ESR1 is linked to depressive disorder.